CD56bright natural killer (NK) cells: an important NK cell subset

Immunology - Tập 126 Số 4 - Trang 458-465 - 2009
Aurélie Poli1, Tatiana Michel2, Maud Thérésine2, Emmanuel Andrès3, François Hentges2, Jacques Zimmer2
1Laboratoire d'Immunogénétique-Allergologie, Centre de Recherche Public de la Santé, Luxembourg-City, Luxembourg.
2Laboratoire d’Immunogénétique‐Allergologie, Centre de Recherche Public de la Santé (CRP‐Santé), Luxembourg‐City, Luxembourg
3Service de Médecine Interne, Clinique Médicale B, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

Tóm tắt

Summary

Human natural killer (NK) cells can be subdivided into different populations based on the relative expression of the surface markers CD16 and CD56. The two major subsets are CD56bright CD16dim/ and CD56dim CD16+, respectively. In this review, we will focus on the CD56bright NK cell subset. These cells are numerically in the minority in peripheral blood but constitute the majority of NK cells in secondary lymphoid tissues. They are abundant cytokine producers but are only weakly cytotoxic before activation. Recent data suggest that under certain conditions, they have immunoregulatory properties, and that they are probably immediate precursors of CD56dim NK cells. CD56bright NK cell percentages are expanded or reduced in a certain number of diseases, but the significance of these variations is not yet clear.

Từ khóa


Tài liệu tham khảo

10.1016/S1471-4906(01)02060-9

10.1073/pnas.0409872102

10.1182/blood-2007-09-077438

10.1111/j.1600-065X.2006.00454.x

10.1016/j.imbio.2007.10.012

10.4049/jimmunol.143.10.3183

10.1002/1521-4141(2001010)31:10<3121::AID-IMMU3121>3.0.CO;2-4

10.1146/annurev.immunol.16.1.359

10.1182/blood.V99.5.1723

10.1111/j.1365-2567.2007.02675.x

10.4049/jimmunol.166.11.6477

10.1159/000237321

10.4049/jimmunol.161.6.2780

10.1006/cimm.1995.1217

10.4049/jimmunol.173.11.6547

10.1189/jlb.0306191

10.4049/jimmunol.162.8.4511

10.4049/jimmunol.172.3.1455

10.1182/blood-2002-09-2876

10.4049/jimmunol.172.3.1333

10.1084/jem.187.12.2065

10.1016/j.jri.2007.04.007

10.1084/jem.20030305

10.1002/eji.200425100

10.4049/jimmunol.173.10.6418

10.1073/pnas.97.7.3400

10.4049/jimmunol.179.1.89

10.4049/jimmunol.178.8.4947

10.1196/annals.1392.001

10.1073/pnas.0611098104

10.1006/meth.1996.0038

10.1371/journal.pone.0001033

10.1002/art.23675

10.1016/j.jaci.2006.04.023

10.1007/s10072-007-0803-3

10.1073/pnas.0601335103

10.4049/jimmunol.174.9.5187

10.1038/ni1582

10.1080/00365540600740520

10.1111/j.1600-0609.2007.00874.x

10.1136/gut.2007.130963

10.1111/j.1365-3083.2008.02116.x

10.1111/j.1365-2567.2008.02887.x

10.1182/blood-2004-05-2058

10.1086/504719

10.1097/01.aids.0000183632.12418.33

10.1016/j.jri.2005.12.008

10.1002/eji.200535243

10.1093/rheumatology/keg240

10.1183/09031936.05.00030805

10.1186/1742-4933-4-3

10.1016/j.jaci.2007.09.047

10.1186/ar1453